When presenting it, M. Schinas stated that the aim is to completely overhaul the entire legislative framework for medicines and pharmaceuticals. 25.11.20 Published today, the EU Pharmaceutical Strategy contains a number of proposals that can help Europe stem the 25-year trend of cutting-edge science and investment leaving Europe for the US and China. The Commission often underlines that the shortcomings in managing the current pandemic has exactly showcased the need for stronger and more assertive EU Industrial and Pharmaceutical strategies. The European Commission published a public consultation on the Pharmaceutical Strategy - Timely Patient Access to Affordable Medicines, which was available for stakeholders to comment on and share their views from 16 June 2020 to 15 September 2020. This pharmaceutical strategy "aims to ensure the quality and safety of medicines, while boosting the sector's global competitiveness" ( European Commission, 2020a ). Why is the Commission presenting this strategy now? When I qualified from university as a biotechnologist it was an exciting time to be in life sciences in Europe, the region was at the forefront of ground-breaking medical innovation. Further information: This strategy aims to create a future-proof regulatory framework and support industry in promoting research and technologies that actually reach patients and fulfil their . On September 28 2021, the EU Commission published a report on the public consultation on the revision of the EU's pharmaceutical legislation, as part of the Pharmaceutical Strategy for Europe (Pharmaceutical Strategy), adopted in November 2020.. 2020-08-27. Such Pharmaceutical Strategy inter alia focuses on supporting a competitive and innovative European pharmaceutical industry, which should ideally go . The strategy is major initiative under the European health union, a process launched by the Commission on 11 November 2020 with a first set of proposals to reinforce preparedness and response during health crises. Pharmaceutical strategy for Europe - implementation, achievements, challenges The Czech Association of Innovative Pharmaceutical Industry, under the auspices of the Czech Presidency of the Council of the EU, organizes a major face-to-face international conference on the topic of Pharmaceutical strategy for Europe. Published: Mar 23, 2020 By Gail Dutton. The new Pharmaceutical Strategy for Europe aims to ensure affordable, safe patient access for the entire European Union. A science-based, competitive and effective regulatory framework: The Roadmap lacks concrete tools to support and encourage clinical development in Europe. It will foster patient access to innovative and affordable 2. It is important as it offers a rare and concise overview of actions and priorities which guide EU policy action. The strategy's goal is to give the EU's pharmaceutical policy a long-term vision: to ensure it is crisis-resilient and sustainable, and to reinforce the EU's position as a global leader in this critical area while ensuring access to affordable medicines for patients. The Pharmaceutical Strategy for Europe aims to ensure Europe's supply of safe and affordable medicines to meet patients' needs and support the European pharmaceutical industry to remain an innovator and world leader. Europe's share of global pharmaceutical revenues in 2021. The strategy, through its objectives described above, is a policy instrument that aims to tackle these important challenges and adapt the EU pharmaceuticals system in the years to come. This pharmaceutical strategy "aims to ensure the quality and safety of medicines, while boosting the sector's global competitiveness" ( European Commission, 2020a ). Today, just 25 years on, 47% of global new treatments are of US . November 24, 2020 The European Commission adopts a pharmaceutical strategy for Europe. Being linked to the new Industrial Strategy, this initiative aims to boost the global competitiveness of the EU . This plan aims to strengthen the European Health Union while ensuring affordable patient access across the entire European Union and supporting sustainable innovation for pharmaceutical industries. Organised by the Directorate-General for Health and Food Safety of the European Commission The Pharmaceutical Strategy for Europe aims to ensure Europe's supply of safe and affordable medicines to meet patients' needs and support the European pharmaceutical industry to remain an innovator and world leader. Projected pharmaceutical sales of the EU in 2025. The first results are starting to show. Eurostat, international trade in goods by type of good. The Pharmaceutical strategy for Europe aims to address these issues by creating a future-proof regulatory framework that supports industry in promoting research and technologies that actually reach patients and fulfil their therapeutic needs while addressing market failures such as the EU's increasing dependence on medicine imports. Considering the . The Pharmaceutical Strategy for Europe has four main objectives: 2. ensuring access to affordable medicines for patients, and addressing unmet medical needs; supporting competitiveness, innovation and sustainability of the EU's pharmaceutical industry and the development of high-quality, safe, effective, and greener medicines; enhancing . Two consultations (on the roadmap and the strategy, respectively), are currently under way. To this end, the strategy lays out a timeline for review of the EU's general legislation on medicines for human use. Advertisement 1. Europe's new pharmaceutical roadmap is designed to reinvigorate innovation in the pharmaceutical industry to make it competitive with the United States. Insists that the pharmaceutical strategy for Europe should consider the objectives of the Zero Pollution Action Plan for water, air and soil; 157. The new Strategy introduces new policies and ideas but also brings into the spotlight long standing challenges which were recently exacerbated by the coronavirus outbreak. By implementing the EMA's 2025 strategy and the Network Strategy, regulatory improvements can be . Next steps The Communication on a Pharmaceutical Strategy for Europe includes a set of actions. Webinar: Implementation of Contamination Control Strategy Using the ECA template. Adopted in November 2020, the Pharmaceutical Strategy for Europe seeks to implement a regulatory framework that supports the pharmaceutical sector in building a stronger, a more robust and resilient supply chain to better fulfil the healthcare needs of European citizens. The next EIPG webinar will be held in conjunction with PIER and University College Cork on Friday 21st of October 2022 (16.00 CEST), on the implementation of Contamination Control Strategy (CCS) using the ECA* template. This document spans a wide range of topics from antimicrobial resistance to reducing the impact of pharmaceuticals on the environment. Overview . On November 25 th 2020, the European Pharmaceutical strategy was published and presented by Commission Vice President Margaritis Schinas and Health Commissioner Stella Kyriakides. Eight months ago, the Commission kicked off the process by publishing its pharmaceutical strategy, a policy document outlining plans to reform EU rules for drugmakers. While everything cannot be captured in this review, one notable initiative includes a . on 25 november 2020, the european commission (the commission) unveiled its pharmaceutical strategy for europe ( pse ), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders ( see, The European Commission's New Pharmaceutical Strategy for Europe Advisory By Jacqueline Mulryne Alexander Roussanov Katya Farkas As part of its vision to build a European Health Union, the European Commission (Commission) announced the new pharmaceutical strategy for Europe (Strategy) on 25 November 2020. On 25 November, the European Commission published its Pharmaceutical Strategy for Europe, which aims to create a "future-proof and resilient" EU pharmaceutical system that enables innovation whilst ensuring the supply of medicines and vaccines to all EU citizens from pharmaceutical distribution experts.. Ahead of a stakeholders' workshop with DG SANTE on 14-15 July, leading civil society organisations outline that it is imperative that the European Commission's new Pharmaceutical Strategy for Europe looks beyond just profit and innovation and takes an holistic approach to safeguarding our health and the health of our environment. The voice of 8 million European public service workers The pharmaceutical strategy for Europe - part 2 (26 October 2021) EPSU welcomed the Pharmaceutical Strategy for Europe and expressed the need to strengthen public research and public companies to deliver quality, affordable and accessible medicines available for all. A new Pharmaceutical Strategy for Europe, published on 25 November has been one of those initiatives, which aim to establish a future-proof and crisis-resilient pharmaceutical system in the EU.. With the EU's new Pharmaceutical Strategy comes an opportunity. EPHA's fourth #A2MDialogue follows the publication of the EU's Pharmaceutical Strategy by the European Commission. 4.3%. About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features Press Copyright Contact us Creators . These cover access to affordable medicine and the . The Pharmaceutical Strategy forms an integral part of the Commission's New Industrial Strategy for Europe, published in March this year. new antimicrobials) lessons learnt from . MEPs welcome new Pharmaceutical Strategy for Europe The European Commission's Strategy, which aims to ensure the supply of medicines and vaccines to all citizens, also seeks to encourage innovation by European pharmaceutical companies. The European Commission's Pharmaceutical Strategy for Europe published last week (25 th November) is intended to ensure robust supply of medicines across the continent so that patients have access to the medication they need, when they need it. coming in the wake of the covid-19 pandemic, the strategy, which will also inform the newly proposed eu4health programme and align with horizon europe for research and innovation, will aim to ensure europe's supply of safe and affordable medicines to meet patients' needs and support the european pharmaceutical industry to remain an innovator and A pharmaceutical strategy for Europe Public Health European Commission Public Health Publications A pharmaceutical strategy for Europe General publications A pharmaceutical strategy for Europe Page contents Details Files Details Publication date 23 February 2021 Author Directorate-General for Health and Food Safety Files These events led to the publication of the EU Pharmaceuticals Strategy in 2020, 1 which, in addition to a range of other activities, aims to ensure the regulatory system for human medicines is futureproof and crisis-resistant. The strategy will have the overall goal of ensuring Europe's supply of safe and affordable medicines and supporting the European pharmaceutical industry's innovation efforts. It rests on four pillars, including legislative and non-legislative action: Ensuring access to affordable medicines for patients, and addressing unmet medical needs (e.g. This report presents a neutral, over-arching review of the replies received. in the areas of antimicrobial resistance, rare diseases); It will foster patient access to innovative and affordable medicines. Entry Strategy for Key Countries: . EUCOPE calls for a comprehensive Pharmaceutical Strategy that adopts a value chain approach . Released by the European Commission on 25 November 2020, the new strategy is a blueprint for the EU's actions in the area of pharmaceuticals in the years to come. Some will make the legislative cut by the end of the current European Commission's term. It will support the competitiveness and innovative capacity of the EU's pharmaceutical industry. Here are a few of the questions #pharma in the #EU needs to consider. And now, as the European Commission pushes to overhaul EU rules for the industry, drugmakers want to see a return on that political capital. The . As part of its vision to build a European Health Union, the European Commission announced the new pharmaceutical strategy for Europe (the new Strategy) on 25 November 2020. The European Commission adopted on 25 November a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU's pharmaceutical industry.